• 1
    Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005; 16: 481488.
  • 2
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106130.
  • 3
    Sekine I, Saijo N. Novel combination chemotherapy in the treatment of non-small cell lung cancer. Expert Opin Pharmacother. 2000; 1: 11311161.
  • 4
    Rosell R, Crino L. Pemetrexed combination therapy in the treatment of non-small cell lung cancer. Semin Oncol. 2002; 29(2 Suppl 5 ): 2329.
  • 5
    Costi MP, Ferrari S, Venturelli A, et al. Thymidylate synthase structure, function and implication in drug discovery. Curr Med Chem. 2005; 12: 22412258.
  • 6
    Nishimura R, Nagao K, Miyayama H, et al. Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res. 1999; 19(6C): 56215626.
  • 7
    Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001; 19: 42984304.
  • 8
    Shiga H, Heath EI, Rasmussen AA, et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res. 1999; 5: 40974104.
  • 9
    Takamura M, Nio Y, Yamasawa K, et al. Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anticancer Drugs. 2002; 13: 7585.
  • 10
    Shintani Y, Ohta M, Hirabayashi H, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer. Lung Cancer. 2004; 45: 189196.
  • 11
    Allegra CJ, Parr AL, Wold LE, et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol. 2002; 20: 17351743.
  • 12
    Allegra CJ, Paik S, Colangelo LH, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2003; 21: 241250.
  • 13
    Merkelbach-Bruse S, Hans V, Mathiak M, et al. Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer. Oncol Rep. 2004; 11: 839843.
  • 14
    Norman P. Pemetrexed disodium (Eli Lilly). Curr Opin Invest Drugs. 2001; 2: 16111622.
  • 15
    Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 26362644.
  • 16
    Hanna N, Shepherd FA, Fossella FV, et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 15891597.
  • 17
    Nakagawa T, Tanaka F, Otake Y, et al. Prognostic value of thymidylate synthase expression in patients with p-Stage I adenocarcinoma of the lung. Lung Cancer. 2002; 35: 165170.
  • 18
    Nakagawa T, Otake Y, Yanagihara K, et al. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer. 2004; 43: 145149.
  • 19
    Hashimoto H, Ozeki Y, Sato M, et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer. 2006; 106: 15951601.
  • 20
    Kuramochi H, Hayashi H, Uchida K, et al. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res. 2006; 12: 2933.
  • 21
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001; 25: 402408.
  • 22
    Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res. 1996; 6: 986994.
  • 23
    Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 2000; 4: 135142.
  • 24
    Lenz HJ, Hayashi K, Salonga D, et al. p53 Point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res. 1998; 4: 12431250.
  • 25
    Rapa I, Volante M, Cappia S, et al. Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. Am J Clin Pathol. 2006; 125: 847854.
  • 26
    Heim W, Wampler GL, Lokich JJ, et al. A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study. J Clin Oncol. 1991; 9: 21622166.
  • 27
    Ichinose Y, Nakai Y, Kudoh S, et al. Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional Phase II trial. Clin Cancer Res. 2004; 10: 43694373.
  • 28
    Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004; 350: 17131721.
  • 29
    Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol. 2005; 23: 49995006.
  • 30
    Nakagawa M, Tanaka F, Tsubota N, et al. A randomized Phase III trial of adjuvant chemotherapy with UFT for completely resected pathological Stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)—the 4th study. Ann Oncol. 2005; 16: 7580.
  • 31
    Adjei AA. Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002; 29(2 Suppl 5 ): 5053.
  • 32
    De Petris L, Crino L, Scagliotti GV, et al. Treatment of advanced non-small cell lung cancer. Ann Oncol. 2006; 17( Suppl 2): ii36ii41.